

Protocol

Biofeedback as a Treatment of Fecal Incontinence or Constipation

(20164)

Medical Benefit		Effective Date: 07/01/13	Next Review Date: 03/18
Preauthorization	No	Review Dates: 09/07, 09/08, 09/09, 09/10, 09/11, 07/12, 03/13, 03/14, 03/15, 03/16, 03/17	

This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: • With fecal incontinence	Interventions of interest are: • Biofeedback	Comparators of interest are: • Medical management • Sphincteroplasty	Relevant outcomes include: • Symptoms • Functional outcomes • Quality of life
Individuals: • With dyssynergia-type constipation	Interventions of interest are: • Biofeedback	Comparators of interest are: • Medical management	Relevant outcomes include: • Symptoms • Functional outcomes • Quality of life
Individuals: • With other types of constipation	Interventions of interest are: • Biofeedback	Comparators of interest are: • Medical management	Relevant outcomes include: • Symptoms • Functional outcomes • Quality of life

Description

Biofeedback is a technique to teach patients self-regulation of physiological processes not generally considered to be under voluntary control; a variety of approaches and devices are available. Among possible indications, biofeedback is proposed as a treatment of fecal incontinence and constipation.

Summary of Evidence

For individuals who have fecal incontinence who receive biofeedback, the evidence includes randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms, functional outcomes, and quality of life. Whereas one RCT found that there was a significantly greater decrease in fecal incontinence symptoms with biofeedback plus exercise training than with exercise training alone, most trials did not show a significant benefit. Systematic reviews have not found that biofeedback provides additional benefit when offered in conjunction with conventional therapy compared with conventional therapy alone. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have dyssynergia-type constipation who receive biofeedback, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, and quality of life. Several well-conducted RCTs focusing on patients with dyssynergia-type constipation have reported benefits in a subgroup of patients meeting well-defined criteria. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have constipation other than dyssynergia-type constipation who receive biofeedback, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, and quality of life. A systematic review of RCTs found a benefit of biofeedback as a treatment for constipation in adults. Conclusions of the systematic review were limited by variability in patient populations, comparator groups, and outcome measures, and biofeedback was not clearly beneficial for any other type of constipation. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy

Biofeedback for constipation in adults may be considered **medically necessary** for patients with dyssynergia-type constipation as demonstrated by meeting all three of the following criteria:

1. Symptoms of functional constipation that meet ROME III criteria (see Policy Guidelines).
2. Objective physiologic evidence of pelvic floor dyssynergia (see Policy Guidelines) demonstrated by inappropriate contraction of the pelvic floor muscles or less than 20% relaxation of basal resting sphincter pressure by manometry, imaging or electromyography (EMG);
3. Failed a three-month trial of standard treatments for constipation including laxatives, dietary changes, and exercises (as many of the previous as are tolerated).

Biofeedback is considered **investigational** as a treatment of constipation in adults and children in all other situations.

Biofeedback is considered **investigational** as a treatment of fecal incontinence in adults and children.

Policy Guidelines

Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders

(http://www.romecriteria.org/assets/pdf/19_Romelll_apA_885-898.pdf) for functional constipation include*:

Rome III diagnostic criteria for functional constipation*:

1. "Must include two or more of the following:
 - a. Straining during at least 25% of defecations
 - b. Lumpy or hard stools in at least 25% of defecations
 - c. Sensation of incomplete evacuation for at least 25% of defecations
 - d. Sensation of anorectal obstruction/blockage for at least 25% of defecations
 - e. Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
 - f. Fewer than three defecations per week
2. Loose stools are rarely present without the use of laxatives
3. Insufficient criteria for irritable bowel syndrome

*Criteria fulfilled for the last three months with symptom onset at least six months prior to diagnosis”

Rome III diagnostic criteria for dyssynergic defecation include:

“Inappropriate contraction of the pelvic floor or less than 20% relaxation of basal resting sphincter pressure with adequate propulsive forces during attempted defecation.”

Guidance on biofeedback protocol:

The recommended treatment course for patients with constipation who meet criteria is up to six biofeedback sessions over three months. This is consistent with the protocol used in key randomized trials showing benefit of biofeedback for selected patients.

Background

Fecal incontinence in adults is the recurrent uncontrolled passage of fecal material. Pathophysiology of the disorder ranges from abnormalities in intestinal motility (diarrhea or constipation) to poor rectal compliance, impaired rectal sensation, or weak or damaged pelvic floor muscles. There is no increase in mortality attributable to fecal incontinence. Morbidity includes skin breakdown and urinary tract infections. Fecal incontinence may affect quality of life by restricting work, recreation, and activities related to “getting out of the house,” impaired social role function, diminished sexual activity, and increase of social isolation due to embarrassment. Fecal incontinence can bring about loss of independence and mobility. It is the second most common reason for elderly institutionalization. The most common causes of fecal incontinence in adults are obstetric trauma coupled with age-related degeneration, previous anorectal surgery, rectal prolapse, and perineal trauma. In many individuals, the condition is multifactorial, involving a combination of structural, physiological, and psychosocial factors. Conventional interventions to treat fecal incontinence include dietary recommendations (e.g., fiber), bowel and toilet scheduling, and medications (e.g., bulking or antidiarrheal agents).

Constipation refers to infrequent bowel movements and difficulty expelling stool during defecation. Primary constipation is generally categorized into three groups. The most common type is normal-transit constipation in which there is a normal rate of stool movement, but patients feel constipated and may complain of abdominal pain and/or bloating. In the second type, slow-transit constipation, stool moves more slowly through the colon and individuals often experience a limited urge to defecate. The third type, dyssynergic defecation, refers to a loss of ability to coordinate contractions of the pelvic floor muscles and to relax the anal sphincter during defecation. Patients often report an inability to defecate despite the urge to do so. There are also secondary causes of constipation such as the use of certain medications, including opioids and psychoactive drugs; neurologic, endocrine, or metabolic disorders; structural abnormalities; and lifestyle factors. Conventional treatment includes dietary changes (i.e., adequate fiber and fluid intake), use of supplemental bulking substances, exercises, and medications.

In children, most cases of fecal incontinence and constipation are functional, in which structural, endocrine, or metabolic diseases have been ruled out. Factors contributing to functional incontinence and constipation are fear and/or pain associated with large, hard stools. This leads to retentive posturing in approximately half the children with chronic constipation (i.e., the avoidance of defecation by purposefully contracting the external anal sphincter, also termed anismus or paradoxical sphincter contraction). Customary or conventional medical intervention includes dietary changes, bowel and toilet scheduling, softening agents, and education. Behavioral interventions aim at restoring normal bowel habits through toilet training, reward and incentive contingency management programs, desensitization of phobia and fear, or skill-building and goal-setting techniques with home practice. Counseling and psychotherapy provide support to the child and address social and psychological problems.

Biofeedback, a technique intended to teach patients self-regulation of certain physiologic processes not normally considered to be under voluntary control, is used for various conditions and is proposed as a treatment of fecal incontinence and constipation.

Biofeedback training for fecal incontinence focuses on improving the ability to voluntarily contract the external anal sphincter and puborectalis muscles in response to rectal filling and to decrease delay in response to a sensation of distension. For constipation, the aim of biofeedback is to teach patients how to tighten and relax their external anal sphincter in order to pass bowel movements.

Biofeedback attempts to improve rectal sensory perception, strength, coordination, or some combination of these three components. Sensory training involves inducing intrarectal pressure using a balloon feedback device. A manometric balloon probe is inserted into the rectum, and the balloon is filled with air to produce a sensation of rectal filling. Strength training uses either anal canal pressure (manometric) or intra-anal electromyography (EMG) feedback of pelvic floor muscles (PFM). The purpose is to strengthen the force of the PFM contraction without including rectal distention. Some training increases endurance (duration of external anal sphincter contraction) as well as peak strength. Coordination training uses pressure feedback of intrarectal balloon distention with a water-perfused catheter or Schuster-type balloon probe and PFM contractions in a simultaneous feedback display. The purpose of coordination training is to synchronize the contraction of the external anal sphincter with relaxation of the internal anal sphincter.

Biofeedback techniques convert the physiologic measures from an intra-anal EMG sensor, anal manometric probe (measuring intra-anal pressure), or perianal surface EMG electrodes to either visual or audio display for feedback. Ultrasound has also been used to show patients' contraction of the anal sphincter on a screen. Biofeedback training is done alone or in combination with other behavioral therapies designed to teach relaxation. Training sessions are performed in a quiet, nonarousing environment.

Regulatory Status

A variety of biofeedback devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. These devices are designated by FDA as class II with special controls and are exempt from premarket notification requirements. FDA defines a biofeedback device as "an instrument that provides a visual or auditory signal corresponding to the status of one or more of a patient's physiological parameters (e.g., brain alpha wave activity, muscle activity, skin temperature) so that the patient can control voluntarily these physiological parameters."

Related Protocols

Biofeedback as a Treatment of Urinary Incontinence in Adults

Sacral Nerve Neuromodulation/Stimulation

Transanal Radiofrequency Treatment of Fecal Incontinence

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced

procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Enck P, Van der Voort IR, Klosterhalfen S. Biofeedback therapy in fecal incontinence and constipation. *Neurogastroenterol Motil.* Nov 2009; 21(11):1133-1141. PMID 19566591
2. Vonthein R, Heimerl T, Schwandner T, et al. Electrical stimulation and biofeedback for the treatment of fecal incontinence: a systematic review. *Int J Colorectal Dis.* Nov 2013; 28(11):1567-1577. PMID 23900652
3. Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. *Cochrane Database Syst Rev.* 2012; 7:CD002111. PMID 22786479
4. Heymen S, Scarlett Y, Jones K, et al. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. *Dis Colon Rectum.* Oct 2009; 52(10):1730-1737. PMID 19966605
5. Bartlett L, Sloots K, Nowak M, et al. Biofeedback for fecal incontinence: a randomized study comparing exercise regimens. *Dis Colon Rectum.* Jul 2011; 54(7):846-856. PMID 21654252
6. Norton C, Chelvanayagam S, Wilson-Barnett J, et al. Randomized controlled trial of biofeedback for fecal incontinence. *Gastroenterology.* Nov 2003; 125(5):1320-1329. PMID 14598248
7. Solomon MJ, Pager CK, Rex J, et al. Randomized, controlled trial of biofeedback with anal manometry, trans-anal ultrasound, or pelvic floor retraining with digital guidance alone in the treatment of mild to moderate fecal incontinence. *Dis Colon Rectum.* Jun 2003; 46(6):703-710. PMID 12794569
8. Brazzelli M, Griffiths P. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. *Cochrane Database Syst Rev.* Apr 19 2006(2):CD002240. PMID 16625557
9. Brazzelli M, Griffiths PV, Cody JD, et al. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. *Cochrane Database Syst Rev.* 2011(12):CD002240. PMID 22161370
10. Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. *Cochrane Database Syst Rev.* 2014; 3:CD008486. PMID 24668156
11. van Ginkel R, Buller HA, Boeckxstaens GE, et al. The effect of anorectal manometry on the outcome of treatment in severe childhood constipation: a randomized, controlled trial. *Pediatrics.* Jul 2001; 108(1):E9. PMID 11433088
12. Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. *Dis Colon Rectum.* Apr 2007; 50(4):428-441. PMID 17294322
13. Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. *Clin Gastroenterol Hepatol.* Mar 2007; 5(3):331-338. PMID 17368232
14. Rao SS, Valestin J, Brown CK, et al. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. *Am J Gastroenterol.* Apr 2010; 105(4):890-896. PMID 20179692
15. Rao SS, Benninga MA, Bharucha AE, et al. ANMS-ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders. *Neurogastroenterol Motil.* May 2015; 27(5):594-609. PMID 25828100
16. Paquette IM, Varma MG, Kaiser AM, et al. The American Society of Colon and Rectal Surgeons' clinical practice guideline for the treatment of fecal incontinence. *Dis Colon Rectum.* Jul 2015; 58(7):623-636. PMID 26200676
17. Paquette IM, Varma M, Ternent C, et al. The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Evaluation and Management of Constipation. *Dis Colon Rectum.* Jun 2016; 59(6):479-492. PMID 27145304

18. American Gastroenterological A, Bharucha AE, Dorn SD, et al. American Gastroenterological Association medical position statement on constipation. *Gastroenterology*. Jan 2013; 144(1):211-217. PMID 23261064
19. National Institute for Health and Clinical Excellence (NICE). Constipation in children and young people: diagnosis and management [CG99]. 2010; <http://www.nice.org.uk/guidance/CG99>. Accessed October 26, 2016.
20. National Institute for Health and Clinical Excellence (NICE). Faecal incontinence: the management of faecal incontinence in adults: management [CG49]. 2007; <https://www.nice.org.uk/guidance/cg49>. Accessed October 26, 2016.
21. Wald A, Bharucha AE, Cosman BC, et al. ACG clinical guideline: management of benign anorectal disorders. *Am J Gastroenterol*. Aug 2014; 109(8):1141-1157; (Quiz) 1058. PMID 25022811
22. National Coverage Determination (NCD) for Biofeedback Therapy (30.1). http://www.cms.hhs.gov/mcd/viewncd.asp?ncd_id=30.1&ncd_version=1&basket=ncd%3A30%2E1%3A1%3ABiofeedback+Therapy. Accessed October 26, 2016.
23. National Government Services, Inc. Local Coverage Determination (LCD): Outpatient Physical and Occupational Therapy Services (L33631), Revision Effective Date for services performed on or after 01/01/2017.